The report on eczema therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global eczema therapeutics market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global eczema therapeutics market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
Report Findings
1) Drivers
- The increasing incidence of eczema is poised to significantly boost the growth of the eczema therapeutics market.
- Increasing research and development activities for development of novel treatments for eczema are anticipated to fuel the growth of the market.
2) Restraints
- Delays in product approvals from the regulatory authorities for the treatment of eczema may restrain the market growth.
3) Opportunities
- The growing availability of sound reimbursement policies for eczema treatment coupled with highly developed medical infrastructure will considerably grow opportunities for the eczema therapeutics market in the upcoming future.
Research Methodology
A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include
1. Company reports and publications2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global eczema therapeutics market is segmented on the basis of drug class, disease indication, and distribution channel.The Global Eczema Therapeutics Market by Drug Class
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Corticosteroids
- Others
The Global Eczema Therapeutics Market by Disease Indication
- Atopic Dermatitis
- Contact Dermatitis
The Global Eczema Therapeutics Market by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Company Profiles
The companies covered in the report include- Pfizer Inc.
- AstraZeneca
- GSK plc.
- Meda AB (acquired by Mylan)
- Sanofi
- Encore Dermatology
- AbbVie Inc.
- Astellas Pharma Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the eczema therapeutics market.2. Complete coverage of all the segments in the eczema therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global eczema therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Pfizer Inc.
- AstraZeneca
- GSK plc.
- Meda AB (acquired by Mylan)
- Sanofi
- Encore Dermatology
- AbbVie Inc.
- Astellas Pharma Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 20.22 Billion |
| Forecasted Market Value ( USD | $ 43.41 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |


